Conference Reports for NATAP

AASLD 61th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010 Back

Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027       Reported by Jules Levin AASLD Nov 2 2010 Boston   Robert Gish1, Naoky Tsai2, Calvin Pan3, Kris Kowdley4, Ke-Qin Hu5, Lai CL6, Ting-Tsung Chang7, Kwang-Hyub Han8, David Cohen9, Hong Tang10, Myron Tong11 1. Division of Hepatology and Complex GI, California Pacific Medical Center, San Francisco, USA; 2. University of Hawaii, Honolulu, USA; 3. Division of Gastroenterology, Mount Sinai School of Medicine, New York, USA; 4. Center for Liver Disease, Virginia Mason Medical Center, Seattle, USA; 5. Division of Gastroenterology, University of California, Irvine Medical Center, Orange, USA; 6. Queen Mary Hospital, Hong Kong, China; 7. National Cheng Kung University Medical College, Tainan, Taiwan; 8. Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 9. Research & Development, Bristol-Myers Squibb Company, Wallingford, USA; 10. Research & Development, Bristol-Myers Squibb Company, Plainsboro, USA; 11. Pfleger Liver Institute, University of California School of Medicine, Los Angeles, USA. * There was one death in the ETV 0.5 mg arm in study ETV-027 on Day 314 due to liver cancer ALT ùare: ALT >2 x baseline and >10 x ULN by clinical laboratory evaluation